Projects per year
Project Details
Description
ABSTRACT
In the United States this year, an estimated 235,760 new lung cancer cases will be diagnosed. The vast
majority of those are attributable to smoking. However, only 11-24% of smokers will develop lung cancer and
the risk among smokers varies significantly. Individual differences in nicotine metabolism can influence that
risk by influencing the intensity of smoking. The primary catalyst of nicotine metabolism is CYP2A6, and we
have demonstrated an association of CYP2A6 activity with the risk of lung cancer. These data are from a
subcohort of ~2200 smokers with nicotine metabolism biomarker data in the Multiethnic Cohort (MEC). The
risk of lung cancer varies across racial/ethnic group as does the contribution of CYP2A6 activity to that risk.
In this project, we propose to develop a genetic score to predict CYP 2A6-catalyzed nicotine metabolism and
to determine the association of that score with the lung cancer risk of ever smokers in the MEC. The gene
that encodes CYP2A6 is notoriously polymorphic. The high homology between CYP2A6 and the pseudogene
CYP2A7, the many variant alleles of each, and their unique distribution by racial/ethnic group complicates the
accurate genotyping of functional variants. However, correctly characterizing an individual's CYP2A6 alleles
is integral to the genotype-guided prediction of nicotine metabolism, and to the complete characterization of
CYP2A6 variation in multiethnic populations. The related gene CYP2D6 has similar genetic complexities and
is equally challenging to genotype. However, recent advances have led to the successful application of long-
range sequencing approaches to accurate CYP2D6 variant calling. We propose to use a similar targeted
sequencing approach to characterize CYP2A6 genetic diversity across racial/ethnic groups. The improved
characterization of CYP2A6 will allow the comprehensive study of the role of CYP2A6 variants in tobacco-
related lung cancer and ultimately better identify those at greatest risk for lung cancer and target them for
prevention strategies. The overall hypothesis of our research is that variation in CYP2A6 activity contributes
to the observed racial/ethnic disparities in lung cancer risk, and that the relative contribution of CYP2A6
activity to risk varies by racial/ethnic group based on the prevalence of metabolically important CYP2A6
variants. The following specific aims are proposed: Aim 1: To characterize the genetic diversity of CYP2A6 in
Native Hawaiians relative to Japanese Americans and Whites. CYP2A6 (and CYP2A7) will be sequenced
using the PacBio SMRTbellTM Sequencing platform. Aim 2: To develop a CYP2A6 genetic score to predict
CYP2A6 nicotine metabolism in the MEC. Aim 3: To investigate the association of the CYP2A6 genetic score
developed in Aim 2 with lung cancer in MEC ever smokers with GWAS data.
Status | Finished |
---|---|
Effective start/end date | 9/1/22 → 8/31/23 |
Funding
- National Cancer Institute: $248,687.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 1 Active
-
Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking
Hecht, S. S., Hatsukami, D. K., Le Marchand, L., Murphy, S. E., Park, S. L., Peterson, L. A., Stepanov, I., Stram, D. O. & Tretyakova, N. Y.
4/1/10 → 8/31/24
Project: Research project